InvestorIdeas.com Newswire; Get stock news , trading alerts and investing articles

Social Networking Stock Alert: LinkedIn (NYSE:LNKD) Trades Up on Fourth Quarter News

2012-02-12T17:41:00.001-08:00

New York, New York - February 10, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including tech stocks issues an investor alert for social networking and media stock, LinkedIn Corporation (NYSE:LNKD). The stock is trading up at $84.64 8.25(10.80%) 10:10AM EST, with a morning high of $86.10. The Company reported its financial results for the fourth quarter and fiscal year ended December 31, 2011 on the close yesterday.

Summary of Results

Revenue for the fourth quarter was $167.7 million, an increase of 105% compared to $81.7 million for the fourth quarter of 2010
Net income for the fourth quarter was $6.9 million, compared to net income of $5.3 million for the fourth quarter of 2010; Non-GAAP net income for the fourth quarter was $13.3 million, compared to $5.2 million for the fourth quarter of 2010. Non-GAAP measures exclude tax-affected stock-based compensation expense and tax-affected amortization of acquired intangible assets
Adjusted EBITDA for the fourth quarter was $34.4 million, or 21% of revenue, compared to $16.3 million for the fourth quarter of 2010, or 20% of revenue
GAAP EPS for the fourth quarter was $0.06; Non-GAAP EPS for the fourth quarter was $0.12
For the full year 2011, revenue increased 115% to $522.2 million from $243.1 million. GAAP EPS increased to $0.11 from $0.07 and Non-GAAP EPS increased to $0.35 from $0.24. Adjusted EBITDA increased to $98.7 million from $48.0 million

"Q4 once again exceeded our expectations for member engagement and business growth. It was a fitting end to a memorable year in which we reinforced our position as the pre-eminent professional network on the web," said Jeff Weiner, CEO of LinkedIn. "We believe continued focus on our members and technology infrastructure positions us well for accelerated product innovation in 2012."
About LinkedIn (NYSE:LNKD)
Founded in 2003, LinkedIn connects the world's professionals to make them more productive and successful. With more than 150 million members worldwide, including executives from every Fortune 500 company, LinkedIn is the world's largest professional network on the Internet. The company has a diversified business model with revenues coming from member subscriptions, marketing solutions and hiring solutions. Headquartered in Silicon Valley, LinkedIn has offices across the globe.
Research Social Networking/ Social Media Stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
http://www.investorideas.com/ TSS/Social_Networking_Stocks.asp
Become an Investor Ideas Member Today - Get 24/7 access to our exclusive members only - 13 stock directories; energy, renewable energy, mining stocks, water, biotech. Added bonus for members - New Tech Stocks Directory for Social Networking and Cloud Computing Stocks
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/ Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Source - Investorideas.com
800-665-0411 - dawn@investorideas.com

Nanotechnology Stocks; mPhase Technologies, Inc. (OTC.BB:XDSL) to File Drug Delivery Patent

2012-02-12T16:52:00.001-08:00

LITTLE FALLS, NJ - February 10, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today that it intends to file a patent based on its Smart Surface technology for a novel drug delivery system.

The drug delivery patent is based on the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Solar News: GM (NYSE:GM) China Headquarters Installs Sunlogics (18L1:GR) GreenZone® Solar Charging Station

2012-02-10T02:07:00.001-08:00

SHANGHAI, China - February 9, 2012 (Investorideas.com renewable energy newswire) General Motors (NYSE:GM) China has completed the installation of the first Sunlogics (18L1:GR) GreenZone® Solar Charging Station at its Shanghai headquarters. Sunlogics, a GM Ventures equity partner, created the GreenZone to be installed at GM's various facilities and dealerships around the world to support the introduction of the Chevrolet Volt extended-range electric vehicle and prepare for future EV vehicle programs. The GreenZone® provides a unique opportunity to charge electric vehicles using a pure renewable energy source, the sun.

"The installation of the GreenZone solar charging station at our GM China headquarters proves our commitment to help develop an electric vehicle charging infrastructure in the Chinese market," said Ray Bierzynski, executive director of electrification strategy for GM China. "GM will continue to play a vital role working with major infrastructure suppliers and electrical utilities to provide convenient, reliable charging solutions for our EV owners now and well into the future."
The GreenZone®Solar Charging Station installed at GM's China headquarters has a rated power output of 10 kW, which is enough to fully recharge up to six Chevrolet Volts each day. The GreenZone installation was completed by China Triumph International Engineering Company, the Sunlogics' Engineering, Procurement and Construction contractor for GM projects.
General Motors and Sunlogics signed a Master Agreement on July 28, 2011, outlining a $7.5 million equity investment in Sunlogics PLC by General Motors Ventures LLC, giving Sunlogics the ability to develop the GreenZoneSolar Charging Station and larger scale commercial solar projects.
"The Sunlogics GreenZone®Solar Charging Station captures energy from the sun and transforms it into clean, green renewable power, which is added to the grid, offsetting electricity used to charge electric vehicles. The GM China Shanghai installation is the first of its kind in China," says Charles Bryant, Sunlogics Interim Chief Executive Officer.
About General Motors (NYSE:GM)
General Motors traces its roots back to 1908. GM has 11 joint ventures, two wholly owned foreign enterprises and more than 35,000 employees in China . GM and its joint ventures offer the broadest lineup of vehicles and brands among automakers in China . Passenger cars and commercial vehicles are sold under the Baojun, Buick, Cadillac, Chevrolet, Jiefang, Opel and Wuling brands. In 2011, GM sold 2.55 million vehicles in China , which represented 8.3 percent growth over the prior year. It has been the sales leader among global automakers in the market for six consecutive years. More information on General Motors in China can be found at GM Media Online.
About Sunlogics (18L1:GR)
Sunlogics PLC is a vertically integrated global solar energy systems provider specializing in solar project development and installation. The scope of the company's operations includes Canada , United States , Europe and China . More information can be found at www.sunlogics.com.
Kevin M. Kelly
GM China Communications
Kevin.M.Kelly@GM.com
86 138 1705 1956
Jessica Feng
GM China Communications
Jessica.Feng@GM.com
021-28987520
Franklin Santagate
Sunlogics PLC
Franklin@sunlogics.com
623-986-1947 (Cell)
Disclaimer
The following information is intended for investors who are able to thoroughly evaluate and accept potential risks related to an investment in shares issued by this company. This information neither presents an offer to sell nor an invitation to buy or subscribe for shares of this company.
The shares of this company are neither admitted to trading on the Regulated Market nor included in trading on the Regulated Market. They are included in trading in the Open Market (Regulated Unofficial Market) of FWB Frankfurter Wertpapierb�rse (the Frankfurt Stock Exchange). Investors must be aware of the fact that the Open Market (Regulated Unofficial Market) on the Frankfurt Stock Exchange is not subject to the high Europe-wide transparency standards and strict provisions for investor protection on EU-regulated markets.
US-Disclaimer
The following web pages are not intended for persons resident in the United States of America , the United Kingdom , Canada , Japan or any country other than Germany . The content of these web pages does not constitute an invitation to buy securities in the United States of America , the United Kingdom , Canada , Japan or any other country than Germany . The securities specified herein are not and will not be registered in the United States of America in accordance with the current valid edition of the U.S. Securities Act of 1933

Nanotechnology Stocks; mPhase Technologies, Inc. (OTC.BB:XDSL) in Negotiations With Private Equity Group

2012-02-10T01:39:00.000-08:00

LITTLE FALLS, NJ - February 9, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) announced today that it is in negotiations with a Private Equity group to invest a minimum of $2 million in mPhase. The Private Equity investment would enable the Company to avoid continuous financings in the public markets and would also bring a new Board Member to the Company with a solid foundation in cost reduction and marketing. This would accelerate the time to market for the Company's products. The acceleration to market in the consumer products area would supplement the Company's continued pursuit to receive government funding for its SmartNanoBattery and other products related to its Smart Surface Technology.

About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Biotech stocks News; BioSante Pharmaceuticals (NasdaqGM: BPAX) Reports Positive LibiGel® Safety Data Review for Phase III Program

2012-02-09T16:05:00.000-08:00

LINCOLNSHIRE, Ill. - February 9, 2012 (Investorideas.com Newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.

BioSante reported that with 3,656 women enrolled and over 5,800 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 31 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.53 percent. In the same population of subjects, there have been 19 breast cancers reported, a rate of approximately 0.33 percent, which is in line with the ages of the subjects enrolled in the study.
"The DMC once again has recommended that the safety study continue as per the FDA-agreed protocol, without modification, as there were no general or specific safety issues based on their unblinded review of adverse events. We are pleased with the low number of CV events to date and we believe it is consistent with the safety of testosterone in this population," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante.
Subjects have been enrolled in this study for an average of 19.3 months. More than 2,500 subjects have been enrolled in the study for more than a year and over 830 subjects have been enrolled for more than two years. The periodic reviews by the DMC are based on their mandate in accordance with FDA agreement on protocol-defined study oversight.
"BioSante's LibiGel Phase III safety study continues," said Stephen M. Simes, BioSante president & chief executive officer. "We plan to meet with the FDA to determine the best path forward for the program, and will make a decision as to the conduct of the LibiGel safety study during the second quarter of this year. We have instituted appropriate cost savings in order to minimize the continuing cost of the safety study. Although LibiGel did not meet the co-primary or secondary endpoints in two Phase III efficacy studies, BioSante continues to investigate alternative strategies to utilize the continuing LibiGel cardiovascular event and breast cancer safety study."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 subjects. The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including, for example, hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
About LibiGel
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). BioSante continues to analyze the LibiGel data from the two pivotal Phase III efficacy trials first reported on December 14, 2011. These trials were double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. Unfortunately, the placebo response in the two efficacy trials was overwhelming; and therefore, LibiGel's results were not shown to be statistically different from placebo. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase I and Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its products and the LibiGel development program, including in particular the LibiGel safety study and the anticipated timing of BioSante's decision whether to continue the safety study, BioSante's future burn rate and cash runway and other statements identified by words such as "will," "continue," "could," "believes," "intends," "expects," "anticipates," "plans," "may," "potential," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, additional analyses of data from the LibiGel efficacy trials and any other LibiGel clinical trials, including the safety study, may be inconsistent with previously announced results or previously conducted clinical trials or may produce negative or inconclusive results; there may be varying interpretations of data produced by clinical trials; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success of clinical testing, the success of BioSante's licensees or sublicensees and BioSante's future revenues, if any, from its licensees and sublicensees; uncertainties relating to the future and costs of BioSante's product development programs, its future burn rate and its need for and ability to obtain additional financing if needed. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release and are based on BioSante's current beliefs and expectations. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other stocks http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: Investorideas.com is paid by BPAX to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (six thousand five hundred per three months of publishing)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

Solar Stock Alert: Suntech Power (NYSE :STP) Trades up over 8%: Solar Industry Shifts to China and U.S.

2012-02-08T13:06:00.000-08:00

New York, NY, - February 8, 2012 – (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for, Suntech Power Holdings Co., LTD (NYSE :STP) , trading up at $3.8998, up 0.2998(8.33%) 3:17PM EST. Several of the Chinese solar stocks were stronger on today’s trading session as reports on the solar sector show a shift to China and US, away from Europe.

About Suntech
Suntech Power Holdings Co., Ltd. (NYSE: STP ) produces industry-leading solar products for residential, commercial, industrial, and utility applications. With regional headquarters in China, Switzerland, and the United States, and gigawatt-scale manufacturing worldwide, Suntech has delivered more than 20 million photovoltaic panels to over 1,000 customers in more than 80 countries. Suntech's pioneering R&D creates customer-centric innovations that are driving solar to grid parity against fossil fuels. Suntech's mission is to provide everyone with reliable access to nature's cleanest and most abundant energy source. For more information about Suntech's people and products, please visit http://www.suntech-power.com.

Research more solar stocks on global stock exchanges –and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus

Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

For more information about Investorideas.com
contact:
800.665.0411

Renewable Energy Stock Alert: FuelCell Energy, Inc. (NasdaqGM: FCEL) Trades up Over 6%

2012-02-08T10:21:00.000-08:00

New York, NY, - February 8, 2012 – (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for, FuelCell Energy, Inc. (NasdaqGM :FCEL) , trading up at
1.19, up 0.07(6.26%) 12:55pm with a high of $1.24.

The last news from the Company in January reported it reached a significant milestone with one billion kilowatt hours (kWh) of ultra-clean and renewable electricity produced by Direct FuelCell(R) (DFC) (R) power plants since 2003. One billion kWh of electricity can power more than 90,000 average size U.S. homes for one year. With more than 80 DFC plants producing environmentally friendly power and usable high quality heat at more than 50 locations globally, DFC plants are eliminating the emission of a significant level of pollutants and substantially reducing carbon emissions compared to the average U.S. fossil-fuel power plant.

About FuelCell Energy
Direct FuelCell(R) power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With over 180 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. The Company's power plants have generated over one billion kWh of power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas. For more information please visit our website at www.fuelcellenergy.com

Research more fuel cell stocks on global stock exchanges –and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus

Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

For more information about Investorideas.com
contact:
800.665.0411

Biotech stocks News; PositiveID Corporation (OTCBB:PSID) Announces Initiation of Clinical Trial of Its Easy Check Non-Invasive Breath Glucose Detection Device

2012-02-08T07:16:00.000-08:00

DELRAY BEACH, Fla. - February 7, 2012 (Investorideas.com newswire) - PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today that it has commenced a clinical trial of its Easy Check(TM) non-invasive breath glucose detection device for people with diabetes. The clinical trial, being held at Schneider Children's Medical Center in Israel, a preeminent research hospital, will initially focus on people with type 1 diabetes and the Company expects to begin recruiting subjects this month.

Currently under development in Israel, Easy Check is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. The Easy Check technology is based on a patent-pending reagent cell that mixes a patient's exhaled air with a proprietary chemical compound, triggering a chemical reaction. The reaction is measured and software in the Easy Check device then interprets the measurement and correlates the patient's acetone level to the level of glucose in the body. The goal of Easy Check is to eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading.
The purpose of the clinical study is to assess the feasibility of Easy Check compared to a standard invasive blood glucose meter and to assess the reliability of Easy Check in measuring blood glucose levels under conditions of altered blood glucose levels. The study will be led by principal investigator Moshe Phillip, Professor and Director of the Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes at Schneider Children's Medical Center of Israel.
Prof. Phillip said, "We are eager to begin testing PositiveID's Easy Check breath device with the hope that one day, Easy Check will offer a non-invasive way to follow the metabolic control of diabetes patients."
PositiveID Chairman and CEO William J. Caragol, said, "After previously announcing positive preliminary laboratory results from testing Easy Check in 2011, this independent clinical study is an important milestone in the advancement of Easy Check. We are very pleased that Prof. Phillip, a world renowned endocrinologist heavily involved in groundbreaking diabetes research, is spearheading this study and we look forward to communicating our progress."
The clinical study has been approved as compliant with the Declaration of Helsinki, which is a set of ethical principles regarding human experimentation developed for the medical community by the World Medical Association.
More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.
Schneider Children's is the only comprehensive, highly specialized care hospital of its kind in the country of Israel and in the Middle East, dedicated exclusively to the well-being of all children and adolescents. Schneider Children's provides the full range of pediatric subspecialties and comprehensive paramedical services to all children. The medical center serves as the national referral center for Hematology-Oncology, Endocrinology and Childhood Diabetes, and Cardiology and is the country's leading institution in the field of bone marrow and organ transplants, such as heart and lung, liver and kidney.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that the Company will launch the first clinical trial of its Easy Check™ non-invasive breath glucose detection device for people with diabetes later this month; the likelihood that the clinical trial will initially focus on people with type 2 diabetes; the likelihood that Easy Check would eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading; the likelihood that the development of Easy Check continues to progress well as evidenced by the imminent launch of the first clinical trial of this potentially revolutionary product later this month; the likelihood that Easy Check could provide a means for people with diabetes to eliminate the pain associated with taking blood glucose readings, therefore facilitating more frequent testing and improved management of this growing disease; the likelihood that iglucose uses wireless technology to empower individuals with diabetes to be more engaged in the self-management of their condition by eliminating the need to keep manual logbooks; the likelihood that iglucose connects to market leading, data capable glucometers to wirelessly and seamlessly communicate blood glucose readings to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose; the Company's ability to complete development of Easy Check and GlucoChip, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Gold Stocks; Gold Bullion (TSX-V: GBB) Adopts Shareholder Rights Plan

2012-02-07T09:11:00.000-08:00

VANCOUVER - February 7, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) ("Gold Bullion" or the "Company") is pleased to announce that it has adopted a shareholder rights plan (the "Rights Plan") designed to encourage the fair treatment of its shareholders in the event of an unsolicited take-over bid for shares of the Company. The Rights Plan is designed to give the Company's shareholders sufficient time to properly assess a take-over bid without undue pressure and to give the Company's Board of Directors time to consider alternatives that allow the Company's shareholders to receive full and fair value for their common shares.

Pursuant to the Rights Plan, each holder of record of the outstanding common shares of the Company on February 1, 2012 will be issued one right per common share. The rights will trade with the common shares and be represented by the certificates representing common shares. Although the Rights Plan is effective immediately, it is subject to TSX Venture Exchange approval and must be ratified by the shareholders of the Company within six (6) months of its adoption. The Rights Plan will be submitted to the shareholders of the Company for ratification at the Annual General and Special Meeting of Shareholders to be held April 12, 2012.
A copy of the Rights Plan is posted and available for viewing on http://sedar.com/.
The Rights Plan is similar to shareholder rights plans adopted by numerous other Canadian corporations. Neither the Board nor senior management of the Company is aware of any current, pending or threatened take-over bid for the Company.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec.
For more information on Gold Bullion Development Corp. (TSXV:GBB.V) (OTCPINK:GBBFF), visit our web site: : www.GoldBullionDevelopmentCorp.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
For further information contact:
Frank J. Basa, P.Eng., President and Chief Executive Officer, Tel: (514) 397-4000
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com

Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.

Mining Stocks; YALE (TSX-V: YLL) DRILLS 10.5 m AVERAGING 1.04 % COPPER AT DOS NACIONES

2012-02-07T08:26:00.000-08:00

VANCOUVER - February 7, 2012 (Investorideas.com Mining stocks Newswire) - Yale Resources Ltd. (TSX-V: YLL, OTCBB: YRLLF, and Frankfurt: YAB) is pleased to report that it has received results for the three holes, drilled on behalf of its optionee Del Toro Silver Corp. (DTOR � OTCBB), at the Dos Naciones property, located in Sonora State, Mexico.
Drilling at Dos Naciones was successful in confirming the presence of multiple outcropping skarn targets. Drilling in the strongly altered and fractured ground proved very difficult and each of the three holes was terminated before reaching the target depth due to technical reasons.
The table below summarizes the results received:
Drill holes D2N-01 and D2N-02 were drilled into and beside, respectively, the La Espanola skarn target, a prominent ridge that is host to numerous historic workings. In addition to the average of 1.04 % copper and 33.3 g/t silver, drill hole D2N-01 intersected an average of 20.7 % iron (using a top cut of 25%) over 10.5 metres from surface. A second zone of mineralization grading 1.5 g/t gold and 88.3 g/t silver over 0.75 m was intersected at a depth of 29.70 m, indicating the potential for additional targets at depth. Drill hole D2N-02 was collared in strongly altered andesitic volcanics with 1 to 3 percent disseminated sulphides but was lost at 12 m before intersecting the target at depth.

Drill hole D2N-03 was drilled into the Dos Naciones Este target, located approximately 2.5 km southwest of drill holes D2N-01 and 02. Hole D2N-03 was collared in an outcrop of skarn and intersected 10.0 m of skarn mineralization averaging 0.76 % copper and 9.3 g/t silver from a depth of 4.5 metres below a zone of very poor recovery.
The size of these targets has yet to be fully tested and as a result Yale is recommending additional drilling at Dos Naciones. Del Toro must spend a total of $800,000 at Dos Naciones prior to July 7, 2013 to earn a 70% interest in the property.
About Yale Resources:
Yale Resources utilizes the project generator business model to maximize its exposure to discovery while minimizing shareholder risk. Yale currently has nine projects in its portfolio of which five are optioned out with commitments totalling approximately $1.3 M in expenditures during the next 12 months. At the same time Yale continues to work on its non-optioned properties as well as reviewing new projects.
Ian Foreman, P.Geo, is Yale�s Qualified Person, according to National Instrument 43-101, for the Dos Naciones properties and is responsible for any technical data mentioned in this news release.
Samples from Dos Naciones were prepared and analyzed by IPL Inspectorate in their facilities in Mexico and Vancouver, respectively. Samples generally consisted of 1-3 kg of material. Gold analyses were performed by 30 gram fire assay with an AA finish. Silver, copper, lead and zinc were analyzed as part of a multi-element ICP package using an aqua regia digestion. Over limit samples with greater than 1% Cu, Pb and Zn were re-analyzed using ore grade detection limits.
On behalf of the Board,
"Ian Foreman"
Ian Foreman, P.Geo.
President
For additional information on Yale Resources please call the Company at 604-678-2531.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.
Contact:
Yale Resources Ltd.
Ian Foreman
604-678-2531

Visit the YLL showcase profile at Investorideas.com
Request News and Info on YLL
Disclosure, Disclaimer/ Investorideas.com is paid by YLL to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)

Biotech Stock on the Move: BioSante (NasdaqGM: BPAX) Trades up over 37%

2012-02-06T12:32:00.001-08:00

New York, New York – February 6, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for
BioSante Pharmaceuticals, Inc. (NasdaqGM: BPAX), trading up at $1.0199, gaining 0.2799(37.82%) 3:10PM EST.

The Company has rebounded from its low of $0.38, now trading above $1.00 with some on the street thinking it can double from here. A follower at Seeking Alpha notes the stock has no real resistance up to $2.01. (http://seekingalpha.com/article/343671-biosante-has-potential-to-double-soon?source=yahoo)

The Company’s last news was a corporate updated issued at the end of January.
http://www.biosantepharma.com/News-Releases.php?ID=013112

.

About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase I and Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member
http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure BPAX is a featured showcase biotech stock on Investorideas.com and has been compensated on average $6500 for 3 months news distribution and content publishing.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com

Biotech Stock to Watch: Complete Genomics (Nasdaq:GNOM) Trades up over 15%

2012-02-06T09:13:00.001-08:00

New York, New York - February 6, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Complete Genomics Inc. (Nasdaq:GNOM). The stock is trading up at $3.46, gaining 0.45 (14.95%) 11:03AM EST on over 1.7 Million shares.
About Complete Genomics (Nasdaq:GNOM)
Complete Genomics is the complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA(TM) Platform) combines Complete Genomics' proprietary human genome sequencing technology with our advanced informatics and data management software. The innovative, end-to-end, outsourced CGA(TM) Service provides customers data ready for genome-based research. Additional information can be found at http://www.completegenomics.com.
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/ Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/ BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news is paid for and /or published as information only for our readers.
Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

First Stop Loss Point Triggered for 2012 Solar Stocks Portfolio; Yingli Green Energy Holding (NYSE:YGE)

2012-02-03T10:47:00.000-08:00

New York, New York- February 3, 2012- Investorideas.com, a leader in renewable energy stock research for independent investors releases solar stocks commentary from solar expert,
J Peter Lynch. Mr. Lynch discusses the first stop loss order for his 2012 solar stocks portfolio, Yingli Green Energy (NYSE: YGE).

Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/
Our first stop loss point for our 2012 Solar Portfolio was triggered this morning with YGE trading below $4.20. We did not question our system; we simply follow it and sold the position for a small gain of 1.92% on the YGE trade.
The current status of the portfolio is an unrealized Gain of 13.92% from the positions we did not sell yet PLUS the 1.92% gain on our stop loss trade.
As a reminder below are the stop loss points I have selected based upon technical support levels in each stock. I have set these stop points very close, since, as I mentioned in the last article I did expect the markets to pull back due to the fact that they are short term overbought.
The stops for the 5 stocks in our Solar Portfolio are.
CSIQ - $3.60
GTAT - $8.25
LDK - $4.70
TSL - $7.50
YGE - $4.20
If any of these stocks reach these levels I would recommend selling that position.
Remember – the number one rule of investing:
Minimize your LOSSES and Maximize your GAINS.
The HARDEST THING for investors to do is know when to sell. That is why you have to set specific, non-emotional prices to exit if things do not go right. You cannot allow your emotions to get involved and take over your thinking.
Remember: markets fool the majority of investors by “Climbing a Wall of Worry” which is exactly what it is doing now. Losses start and keep getting worse when investors get on the “Slides of Hope” and try and hope that their stock comes back – trust me, this is a technique that will NOT work. Trust in your system and follow it.
If you looked at the portfolios of the most successful investors you would, in general, see the following pattern:
Approximately 80% of trades would be either small losses and/or small gains and approximately 20% would be very significant gains. This is exactly how we dramatically outperformed the markets in 2010 and 2011. We cut our losses when things did not work out and we let our profitable stock run and maximize our gains.
Background Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis – this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis – this form of analysis will tell you “when” to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.

Mr. Lynch has worked, for 35 years as a Wall Street security analyst, an independent security analyst and private investor in small emerging technology companies. He has been actively involved in following developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV that was directed at industrial subscribers, such as major energy companies, utilities and governments around the world. He is currently a private investor and has from time to time been a financial/technology consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please visit his website for the promotion of solar energy – www.sunseries.net.
Research more solar stocks on global stock exchanges –and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.

Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp

Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.com® or any of the industry sector portals. At the time of publication, writers may hold positions in the stocks or companies mentioned.

For more information about Investorideas.com contact:
800.665.0411

Optimism Blowing in the Wind for Renewable Energy Stock Zoltek (NASDAQ: ZOLT); Trades up over 40% on First Quarter Report

2012-02-03T08:50:00.001-08:00

New York, NY - February 3, 2012 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for wind stock, Zoltek Companies, Inc. (Nasdaq: ZOLT). The stock is trading up at $13.52 4.05 (42.77%) 10:28AM EST on over 2 Million shares on first quarter earnings.

Zoltek Companies, Inc. (Nasdaq: ZOLT) reported financial results for the first quarter of its 2012 fiscal year.
Zoltek`s net revenues for the quarter ended December 31, 2011, totaled $47.0 million, compared to $32.9 million in the first quarter of fiscal 2011, an increase of 43.2%. On a sequential quarter basis, net sales for the latest quarter increased $3.9 million, or 9.1%, from the fourth quarter of fiscal 2011.
According to the Company pres release, "Zoltek believes that the prospects globally for wind energy will continue to be positive since it is the only clean zero CO2 emission renewable energy source that is cost-competitive with fossil fuels. Moreover, carbon fiber is the only material that delivers the necessary stiffness and strength per pound of weight to ensure the structural integrity of the super-long blades that power these turbines."
Research more electric car stocks on global stock exchanges -and up to 1300 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Social Networking Stocks Continue Run with Facebook Frenzy; FFN, GRPN, LNKD, RENN

2012-02-03T08:08:00.000-08:00

New York, New York - February 3, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including tech stocks issues an investor alert for social networking stocks for the morning of February 3rd as the Facebook IPO frenzy continues to drive the sector. Tech stocks were strong in yesterday�s session, with significant gains in the Social Media/Networking stocks.

Facebook�s pending $5 Billion IPO has investors buying into the sector ahead of its market debut expected in May. Most retail investors know the chance of participating in the IPO are slim and none so they are entering the game with some of the other well known players in the space.
Social Networking stocks Snapshot Trading February 3rd
FriendFinder Networks Inc. (NasdaqGM: FFN) is becoming a best friend to investors this week, trading up again this morning, at 1.3950, up 0.0650(4.89%) 9:54AM EST with a high of $1.47
Groupon, Inc. (NASDAQ: GRPN) is trading up at $23.79, up 0.71(3.07%)
Linkedin Corporation (NYSE:LNKD) is moving up, trading at $79.93, up 2.95(3.83%)
Renren Inc. (NYSE: RENN) is gaining in morning trading, at $5.66, up 0.24(4.43%) 9:58AM EST
SINA Corporation (NASDAQ:SINA) is trading at $76.26, up 0.96(1.27%)
Zynga Inc. (NASDAQ: ZNGA) is running, trading at $13.24, up 0.85(6.90%)
Read the entire S1IPO filing for Facebook: http://www.sec.gov/Archives/edgar/data/1326801/000119312512034517/d287954ds1.htm
Research Social Networking stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
http://www.investorideas.com/TSS/Social_Networking_Stocks.asp
Become an Investor Ideas Member Today - Get 24/7 access to our exclusive members only - 13 stock directories; energy, renewable energy, mining stocks, water, biotech. Added bonus for members - New Tech Stocks Directory for Social Networking and Cloud Computing Stocks
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Source - Investorideas.com
800-665-0411 - dawn@investorideas.com, cvanzant@investorideas.com

Social Networking Stocks Snapshot Following Wednesday's Filing of Facebook IPO; FFN, LNKD, RENN, SINA Trade Up

2012-02-02T09:56:00.001-08:00

New York, New York - February 2, 2012 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including tech stocks issues an investor alert for social networking stocks for February 2nd, following the S1 IPO filing of Facebook Inc, ( Facebook.com) yesterday. The Company is raising $5 Billion in its IPO and intends to start trading in May.

The filing shows revenue of over $3.7 Billion for 2011, up significantly from 2010 revenue of $1.97 Billion.
According to the S1 filing, Facebook had 845 million Monthly Active Users MAUs as of December 31, 2011, an increase of 39% as compared to 608 million MAUs as of December 31, 2010.
Facebook had 483 million daily active users (DAUs) on average in December 2011, an increase of 48% as compared to 327 million DAUs in December 2010. It also had more than 425 million MAUs who used Facebook mobile products in December 2011. There were more than 100 billion friend connections on Facebook as of December 31, 2011. Also noted; users generated an average of 2.7 billion Likes and Comments per day during the three months ended December 31, 2011.
Stocks in the sector are trading up on higher than usual volume on the Facebook boost.
Social Networking stocks Snapshot Trading Snapshot:
FriendFinder Networks Inc. (NasdaqGM: FFN) is trading up at $1.25 0.11(9.65%) with a high of $1.30
Linkedin Corporation (NYSE:LNKD) is trading at $76.41, up 4.04(5.58%) 12:11PM EST with a high of $77.83
Renren Inc. (NYSE: RENN) is trading higher at #5.59, up 0.58(11.58%) 12:16PM EST on volume of over 15 Million shares. The high of the day so far is $5.74.
SINA Corporation (NASDAQ:SINA) is trading up at $75.71 up 1.82(2.46%) with a high of $77.80
The Global X Social Media Index ETF (NasdaqGM: SOCL) that tracks the sector is trading up at 14.99, up 0.40(2.74%) 12:20PM EST.
Read the entire S1IPO filing for Facebook:http://www.sec.gov/Archives/edgar/data/1326801/000119312512034517/d287954ds1.htm
Research Social Networking stocks:
Visit the Investorideas.com Social Networking Stocks Directory preview page:
http://www.investorideas.com/TSS/Social_Networking_Stocks.asp
Become an Investor Ideas Member Today - Get 24/7 access to our exclusive members only - 13 stock directories; energy, renewable energy, mining stocks, water, biotech. Added bonus for members - New Tech Stocks Directory for Social Networking and Cloud Computing Stocks
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Source - Investorideas.com
800-665-0411 - dawn@investorideas.com, cvanzant@investorideas.com

Solar Stocks; J. Peter Lynch Discusses Stop Loss Prices for 2012 Solar Stocks Portfolio

2012-02-01T09:20:00.000-08:00

New York, New York - February 1, 2012 - Investorideas.com, a leader in renewable energy stock research for independent investors releases the following solar stocks commentary from solar expert, J Peter Lynch. Mr. Lynch discusses stop loss orders for his 2012 solar stocks portfolio for investors following his strategy in the sector.
Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/

Stop Loss Prices for 2012 Solar Portfolio

I have received a number of e-mails asking about specific “stop loss” prices for our Solar 2012 Portfolio.
Below are the points I have selected based upon technical support levels in each stock. I have set these stop points very close, since, as I mentioned in the last article I did expect the markets to pull back due to the fact that they are short term overbought.
Solar Stocks remain short term trading stocks, especially ones that are above their 50 day moving average. None of the solar stocks have really formed strong longer term bases – i.e. none of our solar stocks are above their 200 day moving average, a generally accepted sign of longer term strength.
There are two ways that solar stocks can move above their 200 day moving average:

They can shoot up abruptly and in doing so become extremely overbought, or
They can remain a weak sector for a number of months during which the 200 day moving average would drop closer to the current prices at that time.

I think that the second scenario is the far better one for the longer term health of solar stocks and also the most likely.
The stops for the 5 stocks in our Solar Portfolio are.
CSIQ - $3.60
GTAT - $8.25
LDK - $4.70
TSL - $7.50
YGE - $4.20
If any of these stocks reach these levels I would recommend selling that position – YGE is the closest of the 5 to the stop point.
Remember – we want to minimize our LOSSES and maximize our GAINS.
The hardest thing for investors to do is sell when things go wrong. That is why you have to set specific, non-emotional prices to exit if things do not go right.
If you looked at the portfolios of the most successful investors you would, in general, see the following pattern:
Approximately 80% of trades would be either small losses and/or small gains and approximately 20% would be very significant gains. This is exactly how we dramatically outperformed the markets in 2010 and 2011. We cut our losses when things did not work out and we let our profitable stock run and maximize our gains.
Background Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis - this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis - this form of analysis will tell you "when" to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.

Mr. Lynch has worked, for 35 years as a Wall Street security analyst, an independent security analyst and private investor in small emerging technology companies. He has been actively involved in following developments in the renewable energy sector since 1977 and is regarded as an expert in this field. He was the contributing editor for 17 years to the Photovoltaic Insider Report, an early publication in PV that was directed at industrial subscribers, such as major energy companies, utilities and governments around the world. He is currently a private investor and has from time to time been a financial/technology consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please visit his website for the promotion of solar energy – www.sunseries.net.

Read Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/

Read Peter's technical solar stock reviews:
http://www.investorideas.com/PL/Solar-Stocks-Review.asp

Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.com® or any of the industry sector portals. At the time of publication, writers may hold positions in the stocks or companies mentioned.
Research other solar stocks with the renewable energy stocks directory; a global stock directory featuring over 1300 green stocks. Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 12 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information contact Investor Ideas:
Source: www.Investorideas.com

Biotech and Pharma Stock Alert; Aethlon Medical (OTC: AEMD) Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol

2012-02-01T07:49:00.001-08:00

SAN DIEGO - February, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the administration of Hemopurifier® therapy during the first three days of standard of care peginterferon+ribavirin (PR) drug therapy has demonstrated both immediate and rapid virologic responses in genotype-1 infected HCV patients. An immediate virologic response (IVR) represents a 2-log or 100 fold reduction of HCV RNA at day-7 of therapy and rapid virologic response (RVR) is defined as undetectable HCV RNA at day-30 of the 48-week PR regimen. Average HCV RNA reduction during the three day Hemopurifier® + PR treatment window was 98.79%.
It is estimated that approximately 4 million Americans and 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is the leading cause of liver transplant in the U.S. The Hemopurifier® provides rapid real-time clearance of circulating HCV yielding the potential to improve benefit, dose, duration and tolerability of drug therapies without the introduction of drug toxicity and interaction risks. In previous Hemopurifier® studies, average HCV RNA reductions exceeded 50% during four-hour treatment periods without the administration of drug therapy.
"We are extremely pleased with our interim treatment outcomes, which highlight the synergistic potential of Hemopurifier® and drug therapy working in concert to overcome a disease condition," stated Aethlon Chairman and CEO, Jim Joyce. "In addition to our expansive opportunity in hepatitis C, we continue to advance parallel strategies to address HIV, cancer, and sepsis."

Beyond the opportunity to improve PR standard-of-care therapy, Hemopurifier® therapy may also benefit emerging all-antiviral drug cocktails, which face the challenge of overcoming the rate at which viruses attain drug resistance through rapid mutation. The development of drug-resistant strains can occur quickly owing to the extraordinarily high rate of HCV replication. The clearance of circulating hepatitis C virions, including mutant strains, would inhibit the continued replication of drug-resistant viruses and decrease the likelihood of early onset resistance to emerging all-antiviral strategies.
The Extract-1 Study Protocol
The reported results represent interim data from the first three patients treated with Hemopurifier® therapy under the Extract-1 study protocol, which was initiated in the fall of 2011. The clinical site location previously administered Hemopurifier® therapy to non-genotype 1 HCV patients under various treatment schedules. Under the Extract-1 study protocol, hard-to-treat genotype 1 HCV patients are enrolled to receive three 6-hour applications of Hemopurifier® therapy during the first three days of standard of care PR therapy. On day one of the Extract-1 protocol, PR therapy is initiated within one hour of first Hemopurifer® therapy completion. Hemopurifier® therapy is then administered again once daily for the next two days in combination with PR therapy. During the Hemopurifier® treatment periods, patients are free to watch movies, read books, and perform other tasks in the comfort of a clinic setting.
Clinical Endpoint Assessments
The aim of the Extract-1 study protocol is to assess the safety and clinical impact of intermittent Hemopurifier® therapy when combined with the first three days of peginterferon+ribavirin (PR) standard-of-care. To date, Hemopurifier® therapy in Extract-1 treated patients has been well tolerated and without device-related adverse events during the Hemopurifier® + PR treatment period. At present, the reported data of the Extract-1 study is not statistically significant and should be considered preliminary. Changes in HCV RNA levels are measured with the Roche Cobas TaqMan assay, which has a quantification limit of 15 IU per milliliter (iu/ml). In addition to measuring changes in HCV RNA, the Extract-1 study protocol will quantify the amount of HCV captured within Hemopurifier® treatment cartridges. The goal of PR treatment is to establish a sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks after completion of therapy. Primary clinical endpoints of the Extract-1 study measure the impact of Hemopurifier® therapy during the initial phase of PR therapy. Each clinical endpoint is based on changes in HCV RNA from baseline viral load measurements taken prior to Hemopurifier® + PR therapy initiation. These endpoints include:
Day Three (3): the change in HCV RNA from baseline to the end of the Hemopurifier® + PR treatment phase;
Day Seven (7): the change in HCV RNA 7 days from initial baseline. A drop of HCV RNA greater than 2 logs at day 7 is known as an Immediate Virologic Response (IVR). Based on the landmark IDEAL Study of 3,070 HCV genotype-1 patients receiving PR therapy, IVR achievement correlates with 90+% SVR rates, yet is observed in less than 5% of patients;
Day 30: the change in HCV RNA 30 days from initial baseline. Undetectable HCV RNA at day 30 is known as a Rapid Virologic Response (RVR). Based on the IDEAL Study, RVR achievement correlates with an SVR likelihood of 86.2%, which is observed in only 10.35% of patients.
Day 3 Results
Patient E-1.03: Baseline HCV RNA dropped from 5,800,000 IU/ml to 1,840 IU/ml when measured on day 3, representing a 3.49 log reduction. HCV RNA reduction during the 3-day Hemopurifier® + PR treatment phase accounted for 99.96% of the overall HCV RNA reduction reported at day-30.
Patient E-1.02: Baseline HCV RNA dropped from 199,500 IU/ml to 31,550 IU/ml when measured on day 3, representing a 0.80 log reduction. HCV RNA reduction during the 3-day Hemopurifier® + PR treatment phase accounted for 84.21% of the overall HCV RNA reduction reported at day-30.
Patient E-1.01: Baseline HCV RNA dropped from 1,340,000 IU/ml to 54,900 IU/ml when measured on day 3, representing a 1.38 log reduction. HCV RNA reduction during the 3-day Hemopurifier® + PR treatment phase accounted for 95.90% of the overall HCV RNA reduction reported at day-30.
Day 7 Results
On average, the treated patients achieved 2.24 log HCV RNA reduction from baseline at day-7, which is beyond the 2 log reduction that defines the IVR criteria achieved in less than 5% of PR treated patients.
Patient E-1.03: Baseline HCV RNA dropped from 5,800,000 IU/ml to 234 IU/ml when measured on day 7, representing a 4.39 log reduction.
Patient E-1.02: Baseline HCV RNA dropped from 199,500 IU/ml to 17,300 IU/ml when measured on day 7, representing a 1.06 log reduction.
Patient E-1.01: Baseline HCV RNA dropped from 1,340,000 IU/ml to 24,400 IU/ml when measured on day 7, representing a 1.74 log reduction.
Day 30 Results
Two of the three patients achieved a RVR at day 30, which is normally achieved in only 10.35% of patients receiving PR therapy, yet correlates with a 86.2% SVR versus a 30.4% SVR in patients who fail to achieve a RVR. Based on the IDEAL study, it would normally require the enrollment of approximately 20 PR treated patients to accomplish 2 RVR outcomes. It should also be noted that patient E-1.02 missed RVR achievement by 25 iu/ml.
Patient E-1.03: Baseline HCV RNA dropped from 5,800,000 IU/ml to undetectable (<15 IU/ml) when measured on day 30, representing a 5.58 log reduction.
Patient E-1.02: Baseline HCV RNA dropped from 199,500 IU/ml to 40 IU/ml when measured on day 30, representing a 3.69 log reduction.
Patient E-1.01: Baseline HCV RNA dropped from 1,340,000 IU/ml to undetectable (<15 IU/ml) when measured on day 30, representing a 4.95 log reduction.
Beyond high SVR rates, RVR achievement also provides HCV infected individuals the opportunity to reduce PR duration from 48 to 24 weeks (6-month reduction) in RVR patients that maintain undetectable HCV RNA through week 12 of PR therapy. RVR patients are also unlikely to discontinue PR therapy as a result of a non-virological response, which represents the primary reason why 46% of PR therapy patients don't complete their treatment regimen.
RVR achievement also plays a pivotal role in curbing treatment relapse, defined as undetectable HCV RNA at PR completion that again becomes detectable in the 24-week window after therapy completion. As reflected in the IDEAL study, the time to first undetectable HCV RNA correlates with the incidence of treatment relapse. Approximately 50% of patients who achieve complete HCV suppression for the first time by week 24 of therapy suffer from treatment relapse, while less than 10% of RVR patients relapse from therapy.
The Extract-1 study is being conducted at Medanta, The Medicity Institute (Medicity), a $360 million multi-specialty medical institute recently established to be a premier center for medical tourism in India. The principal investigator of the study is Vijay Kher, M.D., Chairman of the Department of Nephrology at the Medanta Kidney & Urology Institute. Dr. Kher previously served as the principal investigator of Hemopurifier® therapy studies conducted at the Apollo and Fortis hospitals in Delhi, India.
Based on the initial Extract-1 study outcomes, Aethlon will seek permission to open up the treatment study to HCV infected individuals who reside outside of India. The company also plans to expand its GMP manufacturing capabilities and upon quantification of HCV capture within Hemopurifier® treatment cartridges, will resubmit an Investigational Device Exemption (IDE) that will request FDA permission to initiate treatment studies in the U.S. The Company is also interested in collaborative clinical opportunities aimed at determining the synergistic effects of Hemopurifier® therapy combined with non-interferon based drug regimens.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome� to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT� system including the ability to introduce a targeted breast cancer therapy known as HER2osome�, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Nanotechnology Stocks Alert; European Premier Technology Research Group Focuses Upon mPhase Technologies (OTC.BB:XDSL) Patent Portfolio

2012-01-31T09:00:00.001-08:00

LITTLE FALLS, NJ - January 31, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) said today, that based upon a scientific review of mPhase's patents, it has received a formal invitation to present its scientific advances in microfluidics at the nanoscale level to a scientific research and development consortium sponsored and funded by a major western European country. Such invitation is only made to a small percentage of high technology companies seeking membership in the Group. If accepted for final membership, mPhase will be afforded the opportunity to receive funding from both governmental sponsored research and an opportunity to utilize its patents in conjunction with those of major multinational companies and receive monies for a myriad of potential product applications. Such opportunity is another example the innovative patent portfolio that mPhase has been able to develop since February of 2004.

A final decision on membership, funding and collaboration and funding from major multinational strategic partners participating in the joint technology research and development group is expected in the spring of 2012.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website:
http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Junior Gold Stocks Alert; SRC (OTCBB: SELR.OB) Announces New Acquisition: Executes LOI to Acquire Billali Gold and Silver Mine

2012-01-31T08:33:00.000-08:00

CAMERON PARK, Calif. - January 31, 2012 (Investorideas.com Mining stocks newswire) Steele Resources Corporation (the "Company," "SRC") (OTCBB: SELR.OB) announced today that it has executed a Letter of Intent to purchase the privately owned Billali Gold and Silver Mine, a near term production gold and silver mine located in the Steeple Rock district in New Mexico. The district has several historic mines in the area, and from 1880 to 1991 an estimated 151,000 ounces of gold, 1,200,000 pounds of copper, 5,000,000 pounds of lead, and 4,000,000 pounds of zinc was mined from the district.

The Billali Gold and Silver Mine has 28 completed diamond core drill holes and a complete NI 43-101 Technical Report. The technical report, authored by Dr. Jan Rasmussen, a 40 year industry veteran states, "based on the historical drilling� the Billali mine could produce over 219,000 tons of ore averaging 12.8 ounces of silver per ton and 0.244 ounces of gold per ton."
CEO Scott Dockter stated, "SRC is an aggressive, growth oriented company and this gold and silver mine fits SRC's acquisition model perfectly. It is too small for major precious metals companies to consider it, yet offers significant potential gold and silver deposits, and is to a stage where it can be put into production this calendar year depending on financing availability."
The Billali Gold and Silver Mine is adjacent to the Summit Mine (owned by Santa Fe Gold Corp) which reports its "diluted Probable Reserve" is "618,070 tons grading 0.143 ounces of gold per ton and 10.78 ounces of silver per ton." According to the Technical Report, "Three quartz veins carrying silver and gold mineralization run the length of the Billali patented lode mining claim. The same quartz vein that is currently being mined for silver and gold at the adjacent Summit Mine continues into the Billali patented claim. These mineralized quartz structures are the target of the Billali mine plan."
Additional information, including the NI 43-101 Technical Report for the Billali Gold and Silver Mine, can be found at www.steeleresources.com.
About Steele Resources
Steele Resources Corporation is a precious metals exploration and development company that is working to become an active gold producer through the development of the 1800 acre Mineral Hill Gold Project and recently announced its intent to acquire the Billali Gold and Silver Mine in New Mexico.
Safe Harbor Statement
The matters discussed in this release do not comply with various SEC guides and regulations including SEC Guide 7 and contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended that involve risks and uncertainties. Although Steele Resources Corp. believes that the expectations reflected in such forward-looking statements are reasonable, the forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected. Steele Resources Corp. cautions investors that any forward-looking statements made by Steele Resources Corp. are not guarantees of future performance and that actual results may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those reflected in forward-looking statements include, but are not limited to, risks and uncertainties regarding the actual mineralization of Steele Resources Corp.'s exploration properties, the unproven nature of and potential changes to Steele Resources Corp.'s business model, the risk that the capital and other resources that Steele Resources Corp. will need to exploit its business model will not be available, and the risks discussed in Steele Resources Corp.'s filings with the Securities and Exchange Commission.
Contact:
Join us on Facebook and Twitter (@SteeleResources)
Newsletter signup and website: www.steeleresources.com
Email: info@steeleresources.com
Scott Dockter Phone: 530.672.6225

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Gold Bullion Development Corp. (TSX-V: GBB) Launches New Website

2012-01-30T09:58:00.000-08:00

January 30, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF) is pleased to announce the launch of their new website. The new site is user friendly and easy to navigate. Investors will find slide presentations highlighting the property's geology including photos of core samples as well as related company information.

The site also features a version entirely in French and has a link to press releases translated into German. Gold Bullion management is considering the addition of other language versions of press releases and will announce such in due course. We invite you to visit the new site at www.GoldBullionDevelopmentCorp.com.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec.
For more information on Gold Bullion Development Corp. (TSXV:GBB.V) (OTCPINK:GBBFF), visit our web site: : www.GoldBullionDevelopmentCorp.com
For further information contact:
Frank J. Basa, P.Eng., President and Chief Executive Officer, Tel: (514) 397-4000
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.

Disclosure, Disclaimer/ Investorideas.com is paid by GBB to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (five hundred per month)

China Stocks Snapshot; China America Holdings, Inc. (OTC.BB: CAAH) Changes Corporate Name to Ziyang Ceramics Corporation

2012-01-30T09:17:00.001-08:00

ZHUCHENG, CHINA - January 30, 2012 - China America Holdings, Inc. (OTC.BB: CAAH) announced today that it has formally changed its corporate name to Ziyang Ceramics Corporation.

China America Holdings acquired Ziyang Ceramic Co., Ltd., a leading manufacturer of high quality interior porcelain tiles in China for use in residential and commercial applications, in June of 2011. The corporate name change completes the company's repositioning efforts of its acquisition of Ziyang Ceramic and its tile manufacturing and distribution business in China. For the first nine months of 2011, Ziyang Ceramics recorded revenue of $29.4 million with net income of $7.1 million compared to revenue of $22.9 million and net income of $5.7 million in the first nine months of 2010. After giving effect to the reverse stock split which became effective on January 27, 2012, the company has approximately 10 million shares of common stock outstanding with shareholder equity of $17.9 million as of September 30, 2011.
It is anticipated that the company's trading symbol will be changed in the near future to reflect its new corporate name. Stockholders are not required to take any action with respect to the change in the corporate name, the reverse stock split or any proposed changes to its trading symbol. For more information about Ziyang Ceramics Corporation, please visit: www.ziyangcorp.com.
Commenting on the name change, Mr. Lingbo Chi, CEO of Ziyang Ceramics Corp., stated, "We are very excited to complete our corporate transformation to Ziyang Ceramics Corporation in the U.S. We begin 2012 with a focused business strategy to continue the growth of our porcelain tile business. We have added new products in 2011 within our current distribution base and we plan to continue to expand our footprint in China as well as other global markets in the coming quarters and years. We are excited to move forward with our efforts to build on our recent performance and grow our revenue and earnings for the benefit of our stockholders."
About Ziyang Ceramics Corporation
Ziyang Ceramics Corporation, headquartered in Zhucheng city of Shandong Province in China, manufactures porcelain tiles used for interior residential and commercial applications and sells through a distribution network of more than 150 distributors across 10 provinces, concentrating on major second and third tier cities located primarily in Eastern and Central China. For more information about Ziyang Ceramics Corporation, please visit: www.ziyangcorp.com.
Safe Harbor Statement
Ziyang Ceramics Corporation is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding the growth of our sales and distribution network and our expectations regarding revenues and earnings.
We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended September 30, 2010 and in our Current Report on Form 8-K/A as filed with the SEC on October 26, 2011.
Contact:
Ziyang Ceramics Corporation
U.S. Representative
Pearl Group Advisors
Dore Perler
Tel: (954) 232-5363
Email: Dore@PearlGroupAdvisors.com

China America Holdings (OTC.BB:CAAH.OB) is a featured stock on Investorideas.com
Visit the company profile

Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

China Stock Alert: CD International Enterprises (NASDAQ: CDII) to Host Networking Event for Business Partners and Investors on Monday, February 6th at its Headquarters in Deerfield Beach, Florida

2012-01-30T08:29:00.001-08:00

DEERFIELD BEACH, FL - January 30, 2012 (InvestorIdeas.com Newswire) - China Direct Industries, Inc., d/b/a CD International Enterprises ( NASDAQ:CDII), a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas and provides cross border corporate advisory services announced today that it will host a networking event from 4:00 pm to 9:00 pm on Monday February 6, 2012 at its worldwide headquarters located at 431 Fairway Drive, Suite 200, Deerfield Beach, Florida. Management invites its business partners, investors, and consultants to join us at this event as we look to expand our business network in 2012. Parties interested in attending the event should contact Peisha Shen at (954) 363-7325 or email Peisha at Peisha.shen@cdii.net.

In addition, as part of our effort to expand our corporate communications, we recently updated our website and have developed several social media sites to provide updates on our business.
To follow CD International Enterprises and register for our promotional giveaways please visit http://www.cdii.net/index.php/web-20.
About CD International Enterprises
China Direct Industries, Inc. d/b/a CD International Enterprises (NASDAQ: CDII), is a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas and provides business and financial consulting services. Headquartered in Deerfield Beach, Florida with corporate offices in Shanghai, CD International Enterprises' unique infrastructure provides a platform to expand business opportunities globally while effectively and efficiently accessing the U.S. capital markets. For more information about CD International Enterprises, please visit http://www.cdii.net.
Contact Information:
China Direct Industries, Inc.
Richard Galterio or Lillian Wong
Investor Relations
Phone: 1-877-China-57
Email: richard.galterio@cdii.net
lillian.wong@cdii.net

CD International Enterprises (NasdaqGM:CDII) is a featured stock on Investorideas.com
Visit the company profile

Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings , news , SEC filings and or company comments and quotes. CD International Enterprises (NasdaqGM: CDII) One month online marketing paid for by third party Pearl Group; twelve thousand five hundred, to include CFA Commentary, email distribution with other Investorideas.com partners and network of online media which are also compensated as part of this overall marketing (please read their disclosures)

Solar Stocks Commentary with J Peter Lynch; Market Continues to turn Positive

2012-01-30T08:10:00.000-08:00

2012 Solar Stocks Portfolio Sees Gains of over 13% to Date
New York, NY - January 30, 2012 (Investorideas.com renewable energy stocks newswire) www.Investorideas.com, a leader in renewable energy and cleantech stock research for independent investors issues market and solar stocks commentary from solar expert, J. Peter Lynch, a regular columnist at Investorideas.com
Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/

As I mentioned in my last article most of my indicators (technical) have turned positive and despite all the terrible news in the press about the U.S. economy and in Europe what appears to be happening NOW is a buying opportunity.
There is an old saying that a rising tide lifts ALL boats.
The solar sector has literally been destroyed and NONE of the stocks in our solar stock list have given a strong longer term buy signal � but I have gotten so many e-mails regarding what to buy if an investor wants to �bottom fish� in the solar area.
I took a look at the sector over the past few days and we �bought� (simulated, not actual) the following 5 solar stocks yesterday (1-10-2012) at the close these are the best five stocks, in my opinion, if you want to take a chance and bottom fish in the solar industry sector. But keep in mind this is a trading play and should be classified as higher risk money. An additional positive note - all five of these stocks has given a short term �buy� by trading above its 50 day moving average.
The portfolio has done extremely well in only 3 weeks and certainly it would not be a terrible idea to take all your profits or at least sell � of your positions. We are going to set very close stop orders (orders to sell) at roughly 10% below the closing prices on Friday to protect our profits and yet also let some of these profits run if their respective stocks continue to climb.
2012 Solar Portfolio

Stock	Buy Price	# shares	Current Price	% Gain
csiq	3.1	1,000	3.92	26.5
gtat	7.99	1,000	8.75	9.5
ldk	4.68	1,000	4.91	4.9
tsl	7.3	1,000	8.67	18.8
yge	4.12	1,000	4.54	10.2
			Portfolio Gain	13.20%

** All stocks purchased at the closing price on 1/10/2012
** Current prices are the closing prices on Friday the 27th

The General Markets
At the current time the general markets are short term very overbought (i.e. run up too far to fast) I would not be surprised to see a 5% or so correction here and then the market continue its upward movement. Most of my longer term indicators are positive and getting stronger, so I would only expect the next move, if downward, to be a short term move.
In addition, the solar stocks seems to be getting a little attention because of the oil situation and all the new "noise" in the middle east with Iran - this could give our stocks a little bit of a run up and we are positioning ourselves (with the stops) to cut any losses short but also potentially take advantage of a short term run up in prices due to oil related news by letting our profits run higher.
Background Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis - this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis - this form of analysis will tell you "when" to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.

Read Solar Stocks Commentary with J Peter Lynch at Investorideas.com
http://www.investorideas.com/PL/

Read Peter's technical solar stock reviews:
http://www.investorideas.com/PL/Solar-Stocks-Review.asp

Biotech Medical Stock News: PositiveID Corporation (OTCBB:PSID) Obtains Certification from AT&T for iglucose Mobile Health System for Individuals with Diabetes

2012-01-30T07:50:00.001-08:00

DELRAY BEACH, FL - January 30, 2012 (Investorideas.com Newswire) Medical Stock Alert; PositiveID Corporation (OTCBB: PSID), a developer of medical technologies for diabetes management, announced today it has obtained certification from AT&T for PositiveID's iglucose™ mobile health system, designed to simplify diabetes management for the millions of individuals impacted by this growing disease. This certification gives PositiveID's FDA-cleared iglucose system access to the AT&T network, which has the largest global presence of any U.S.-based wireless provider.

iglucose is the first and only pocket sized, FDA cleared, mobile health device specifically designed to connect to industry leading glucometers to transmit blood glucose readings anytime, anywhere. By seamlessly communicating glucose readings from a glucometer to the iglucose diabetes management portal, this important data can be shared with family members, caregivers and healthcare professionals via text message, email or fax, or through the iglucose diabetes management portal itself. iglucose makes it easier for individuals with diabetes to manage their disease and provides healthcare professionals with better data that can be used to improve clinical insight and treatment decisions.
Laboratory testing for the iglucose device was conducted in AT&T's wireless device testing laboratory. During certification, AT&T subjects each device to a series of rigorous tests to ensure the operational reliability of each unit as well as its ability to function flawlessly across the entire AT&T wireless network. iglucose is specifically designed for mobile monitoring, which helped to ensure optimum performance of the device during testing.
While medical devices for home monitoring have existed for many years, the devices are typically large, expensive and not targeted solely for the diabetes population. iglucose was designed with the end user in mind; the iglucose device fits easily into the pouch individuals with diabetes typically carry containing their blood glucose meter and test strips. Furthermore, because iglucose does not require a phone line or internet connection, its portability and compact size mean it can be used anywhere, anytime.
The iglucose system is compatible with market-leading glucometers such as Johnson & Johnson LifeScan®, Nipro Diagnostic™ True™, Abbott Freestyle®, and Bayer Breeze® and Contour® meters.
PositiveID Chairman and CEO William J. Caragol, said, "AT&T certification, which is not easily achieved, is an important confirmation of the performance and dependability of iglucose . As we continue to prepare to roll-out this mobile health system early this year through pilot programs with insurers and home-healthcare providers, AT&T certification provides us significant validation upon which our customers and partners can rely."
More than 25 million children and adults in the U.S. have diabetes, or over eight percent of the population, according to the 2011 National Diabetes Fact Sheet . The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit http://www.PositiveIDCorp.com .
For more information on iglucose, please visit http://www.iglucose.com . For sales and partnership opportunities, please contact Mary Ellen Harrison at 561-805-8028 or meharrison@positiveidcorp.com.
Statements about PositiveID's future expectations, including the likelihood that AT&T certification gives PositiveID's FDA-cleared iglucose system access to the AT&T network, which has the largest global presence of any U.S.-based wireless provider; the likelihood that iglucose makes it easier for individuals with diabetes to manage their disease and provides healthcare professionals with better data that can be used to improve clinical insight and treatment decisions; the likelihood that because iglucose does not require a phone line or internet connection, its portability and compact size mean it can be used anywhere, anytime; the likelihood the iglucose system is compatible with market-leading glucometers such as Johnson & Johnson LifeScan, Nipro Diagnostic True, Abbott Freestyle, and Bayer Breeze and Contour meters; the likelihood that AT&T certification, which is not easily achieved, is an important confirmation of the performance and dependability of iglucose; the likelihood that as PositiveID continues to prepare to roll-out this mobile health system early this year through pilot programs with insurers and home-healthcare providers, AT&T certification provides PositiveID significant validation upon which its customers and partners can rely; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Published at the Investorideas.com Newswire and syndicated blogs
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation ( OTCBB:PSID ) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894